Clinical Trial

Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 3, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous BCMA/CD70-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-28.
Trial Details
NCT Number NCT07318259
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Conditions Systemic Lupus Erythematosus
Enrollment 18 participants
Start Date 2026-01-26
Primary Completion 2026-07 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-03